Doing things out of proper sequence can require a do-over.  But in law, as elsewhere, the do-over may come too late. 

Just ask Abraxis, a drug maker that today lost a lawsuit because the company it bought patents from didn't own them at the time.

Abraxis signed an Asset Purchase Agreement with AstraZeneca in April 2006. 

The Ninth Circuit today took pains to express its disdain for counsel's role in goading a district judge into Kafkaesque rulings. 

Holding that the district court abused its discretion in denying a request for more time and erred in granting summary judgment (and awarding almost $250,000 in attorney's fees!) against the plaintiff, who claimed to have

Russian scientists come up with a way to make an ozone-friendly agent that helps prepare materials useful in making units that store hot or cold.  They tell the American company that hired them about the results of their study.  And the U.S. firm starts using the process that their Russian colleagues discovered.

Does the U.S. outfit qualify

Blawgletter recalls early on hearing about "the bow tie rule".  People who wear bow ties, the rule supposes, want to stand out.  They regard themselves as unique.  They desire others to see visible proof of their disdain for norms, wardrobe-wise and otherwise.  And you don't want them on your jury.  They'll tend to disagree with other